BR112018005316A2 - ?uso de lisina para restabelecer/aumentar a atividade antibacteriana na presença de surfactante pulmonar de antibióticos inibidos desse modo? - Google Patents

?uso de lisina para restabelecer/aumentar a atividade antibacteriana na presença de surfactante pulmonar de antibióticos inibidos desse modo?

Info

Publication number
BR112018005316A2
BR112018005316A2 BR112018005316-3A BR112018005316A BR112018005316A2 BR 112018005316 A2 BR112018005316 A2 BR 112018005316A2 BR 112018005316 A BR112018005316 A BR 112018005316A BR 112018005316 A2 BR112018005316 A2 BR 112018005316A2
Authority
BR
Brazil
Prior art keywords
pulmonary surfactant
lysine
antibiotics
restore
inhibited
Prior art date
Application number
BR112018005316-3A
Other languages
English (en)
Inventor
Wittekind Michael
Schuch Raymond
Original Assignee
Contrafect Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Contrafect Corporation filed Critical Contrafect Corporation
Publication of BR112018005316A2 publication Critical patent/BR112018005316A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462—Lysozyme (3.2.1.17)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017—Lysozyme (3.2.1.17)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

a presente divulgação se refere aos métodos para restabelecer ou aumentar a atividade bactericida de um antibiótico em um órgão ou tecido no qual o surfactante pulmonar está presente. mais especificamente, a presente divulgação descreve que a inibição de antibióticos devido aos fatores ambientais, tais como a presença de surfactante pulmonar em um órgão ou tecido, tal como o epitélio respiratório, pode ser contornada ou superada e a eficácia do antibiótico naquele meio restabelecida ou aumentada pela co-administração de um antibiótico e uma lisina.
BR112018005316-3A 2015-09-17 2016-09-16 ?uso de lisina para restabelecer/aumentar a atividade antibacteriana na presença de surfactante pulmonar de antibióticos inibidos desse modo? BR112018005316A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562220212P 2015-09-17 2015-09-17
US62/220,212 2015-09-17
US201562247619P 2015-10-28 2015-10-28
US62/247,619 2015-10-28
PCT/US2016/052348 WO2017049242A2 (en) 2015-09-17 2016-09-16 Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited thereby

Publications (1)

Publication Number Publication Date
BR112018005316A2 true BR112018005316A2 (pt) 2018-12-11

Family

ID=57121513

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112018005318-0A BR112018005318A2 (pt) 2015-09-17 2016-09-16 ?polipeptídeos de lisina ativos contra bactérias gram-negativas?
BR112018005316-3A BR112018005316A2 (pt) 2015-09-17 2016-09-16 ?uso de lisina para restabelecer/aumentar a atividade antibacteriana na presença de surfactante pulmonar de antibióticos inibidos desse modo?

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR112018005318-0A BR112018005318A2 (pt) 2015-09-17 2016-09-16 ?polipeptídeos de lisina ativos contra bactérias gram-negativas?

Country Status (15)

Country Link
US (5) US10744189B2 (pt)
EP (4) EP3349780B1 (pt)
JP (3) JP7029805B2 (pt)
KR (2) KR20180064417A (pt)
CN (3) CN108135971A (pt)
AU (3) AU2016324298B2 (pt)
BR (2) BR112018005318A2 (pt)
CA (2) CA2998507A1 (pt)
ES (1) ES2934714T3 (pt)
HK (1) HK1256628A1 (pt)
IL (2) IL258123B (pt)
MX (3) MX2018003101A (pt)
RU (2) RU2728682C2 (pt)
WO (2) WO2017049242A2 (pt)
ZA (2) ZA201801316B (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230135161A (ko) * 2012-05-09 2023-09-22 콘트라펙트 코포레이션 박테리오파지 리신을 이용한 생물막의 예방, 붕괴 및 치료
BR112016030580B1 (pt) * 2014-06-26 2023-12-19 The Rockefeller University Polipeptídeo de lisina e fragmento de polipeptídeo com atividade para matar bactérias gram-negativas
CN104805066B (zh) * 2015-05-18 2018-04-24 武汉菲吉乐科生物科技有限公司 一种葡萄球菌裂解酶及其应用
RU2728682C2 (ru) * 2015-09-17 2020-07-31 Контрафект Корпорейшн Применение лизина для восстановления/увеличения антибактериальной активности антибиотиков в присутствии легочного сурфактанта, который ингибирует указанные антибиотики
AU2018384790A1 (en) * 2017-12-12 2020-07-30 Contrafect Corporation Identification of lysins and derivatives thereof with bacterial activity against pseudomonas aeruginosa
WO2019126670A1 (en) 2017-12-22 2019-06-27 The Rockefeller University Recombinant pseudomonas aeruginosa lysins
CA3087228A1 (en) 2017-12-28 2019-07-04 Consegna Pharma Inc. Long acting opioid antagonists
CN112368376A (zh) * 2018-03-29 2021-02-12 康特拉费克特公司 溶素-抗微生物肽(amp)多肽构建体、溶素、其分离的编码多核苷酸及其用途
CN112368010A (zh) * 2018-03-29 2021-02-12 康特拉费克特公司 抗微生物的、细菌噬菌体来源的多肽及其针对革兰氏阴性细菌的用途
US10988520B2 (en) * 2018-03-29 2021-04-27 Contrafect Corporation Lysin-antimicrobial peptide (AMP) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
EP3813796A4 (en) * 2018-05-23 2022-06-22 The Rockefeller University RECOMBINANT LYSINE
BR112020026267A2 (pt) * 2018-06-22 2021-04-06 Contrafect Corporation Lisinas e seus derivados resensibilizam novamente staphylococcus aureus e bactérias gram-positivas aos antibióticos
CN110664881A (zh) * 2018-07-03 2020-01-10 上海海洋大学 抗水产致病性弗氏柠檬酸杆菌的药物及其制备方法
KR20210049023A (ko) * 2018-08-23 2021-05-04 콘트라펙트 코포레이션 리신-항미생물 펩타이드(amp) 폴리펩타이드 작제물, 리신, 이를 인코딩하는 단리된 폴리뉴클레오타이드 및 이의 용도
US20220024992A1 (en) * 2018-11-02 2022-01-27 The Rockefeller University Compositions and methods comprising lysocins as bioengineered antimicrobials for use in targeting gram-negative bacteria
AU2020244764A1 (en) * 2019-03-22 2021-10-14 Contrafect Corporation Method of treating infective endocarditis
BR112021019430A2 (pt) * 2019-04-05 2021-11-30 Contrafect Corp Lisinas e seus derivados com atividade bactericida contra pseudomonas aeruginosa, na presença de soro humano
EP3996740A4 (en) * 2019-07-12 2023-07-05 Contrafect Corporation THERAPEUTIC PROTEIN FORMULATIONS INCLUDING ANTIBODIES AND THEIR USES
CN110684760A (zh) * 2019-09-27 2020-01-14 吉林大学 一种杀灭葡萄球菌的基因工程裂解酶及制备方法和应用
CA3175024A1 (en) 2020-03-11 2021-09-16 Telum Therapeutics S.L. New recombinant lysin and its use in the treatment of gram-negative bacterial infections
WO2021207679A1 (en) * 2020-04-10 2021-10-14 Liberty Biosecurity, Llc Polypeptide compositions and uses thereof
US20210324359A1 (en) * 2020-04-17 2021-10-21 Contrafect Corporation Use of gram-negative lysin-antimicrobial peptide (amp) polypeptide constructs in treating endocarditis
JP2023526388A (ja) * 2020-05-22 2023-06-21 ライセンテク カンパニー リミテッド 新規なポリペプチド、融合ポリペプチド、およびこれを含むグラム陰性菌に対する抗生物質
KR102224897B1 (ko) * 2020-05-22 2021-03-08 주식회사 라이센텍 신규한 폴리펩타이드 및 이를 포함하는 그람음성균에 대한 항생제
KR102228999B1 (ko) * 2020-08-27 2021-03-18 주식회사 라이센텍 폴리펩타이드 변이체 및 이를 포함하는 그람음성균에 대한 항생제
KR102419028B1 (ko) * 2021-01-06 2022-07-08 주식회사 리신바이오 박테리오파지 유래 신규 재조합 엔도라이신 및 이의 용도
US11452757B2 (en) * 2021-02-25 2022-09-27 Intron Biotechnology, Inc. Antibacterial composition effective in treating gram negative bacterial infections and method for preparing the same
WO2023018199A1 (ko) * 2021-08-09 2023-02-16 주식회사 레고켐바이오사이언스 신규 항생제 및 이의 용도
WO2023034646A2 (en) * 2021-09-03 2023-03-09 Aanika Biosciences, Inc. Lysecd7 variants and methods of using the same
US11548917B1 (en) * 2021-11-24 2023-01-10 Intron Biotechnology, Inc. Antibacterial composition effective in treating gram negative bacterial infections and method for preparing the same
WO2023139605A1 (en) * 2022-01-20 2023-07-27 Techinvention Lifecare Pvt. Ltd. Lysin polypeptides and compositions thereof against urinary tract infection caused by drug-resistant gram- negative bacteria

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003247881A1 (en) 2002-07-08 2004-01-23 Joe S. Wilkins Jr. Antibacterial formulations
CN101094427B (zh) 2006-06-23 2010-05-12 华为技术有限公司 全网信令消息采集系统及方法
KR101717275B1 (ko) * 2007-07-26 2017-03-16 레반스 테라퓨틱스, 아이엔씨. 항미생물 펩티드, 조성물, 및 이용 방법
KR20170024129A (ko) 2009-06-26 2017-03-06 카톨리에케 유니버시테이트 루벤 항균제
MX2012002216A (es) 2009-08-24 2012-04-10 Univ Leuven Kath Nueva endolisina obpgplys.
CN102021161A (zh) 2009-09-22 2011-04-20 昆山博青生物科技有限公司 一种制备肺炎链球菌噬菌体裂解酶的方法
JP6058540B2 (ja) * 2010-09-17 2017-01-11 テクニファー−インダストリア テクニカ ファーマシューティカ，エス．エー． 抗菌性ファージ、ファージペプチド、及びそれらの使用方法
EP2468856A1 (en) 2010-12-23 2012-06-27 Lysando Aktiengesellschaft Antimicrobial Agents
JP5187460B2 (ja) * 2011-02-22 2013-04-24 Ｄｉｃ株式会社 水性ウレタン樹脂組成物及びそれを用いて得られるフィルム及び光学フィルム
AU2012245357B2 (en) 2011-04-21 2017-06-08 The Rockefeller University Streptococcus bacteriophage lysins for detection and treatment of gram positive bacteria
EP2702070B1 (en) 2011-04-27 2015-09-30 Lysando AG New antimicrobial agents
WO2013044055A2 (en) 2011-09-23 2013-03-28 Quantum Engineered Products, Inc. Low profile jack
US10813983B2 (en) * 2012-05-09 2020-10-27 Contrafect Corporation Bacteriophage lysin and antibiotic combinations against gram positive bacteria
EP2679677A1 (en) 2012-06-29 2014-01-01 Lysando Aktiengesellschaft Composition for use in Mycobacteria therapy
US9139626B2 (en) * 2012-09-13 2015-09-22 The Mitre Corporation Mitrecin A polypeptide with antimicrobial activity
US10502652B2 (en) 2013-01-29 2019-12-10 Wideco Sweden Ab System for monitoring pipeline leakage, pipeline element provided with the system, and method for mounting the monitoring system onto a pipeline
WO2014124047A1 (en) 2013-02-06 2014-08-14 Academia Sinica Antimicrobial peptides derived from hepatitis b virus core protein arginine-rich domain
WO2015070912A1 (en) 2013-11-14 2015-05-21 Lysando Ag Modified el188 endolysin sequence
WO2015070911A1 (en) 2013-11-14 2015-05-21 Lysando Ag Modified kz144 endolysin sequence
RU2728682C2 (ru) * 2015-09-17 2020-07-31 Контрафект Корпорейшн Применение лизина для восстановления/увеличения антибактериальной активности антибиотиков в присутствии легочного сурфактанта, который ингибирует указанные антибиотики

Also Published As

Publication number Publication date
KR20180064417A (ko) 2018-06-14
US20220362352A1 (en) 2022-11-17
US20190070269A1 (en) 2019-03-07
EP3349780A2 (en) 2018-07-25
US20200376096A1 (en) 2020-12-03
AU2016324307B2 (en) 2021-10-21
RU2018107245A (ru) 2019-10-18
WO2017049233A2 (en) 2017-03-23
MX2018003101A (es) 2018-12-17
CA2998484A1 (en) 2017-03-23
CN108348574B (zh) 2022-11-01
IL258123B (en) 2021-03-25
BR112018005318A2 (pt) 2018-12-11
EP4151228A3 (en) 2023-06-14
CN108348574A (zh) 2018-07-31
EP3349781A2 (en) 2018-07-25
US11357833B2 (en) 2022-06-14
IL258122B (en) 2020-08-31
EP3349780B1 (en) 2022-11-09
WO2017049233A3 (en) 2017-06-01
WO2017049242A3 (en) 2017-06-01
ZA201801316B (en) 2018-11-28
US10744189B2 (en) 2020-08-18
ZA201801315B (en) 2018-11-28
CN116077630A (zh) 2023-05-09
US20190290672A1 (en) 2019-09-26
IL258123A (en) 2018-05-31
US20230050560A1 (en) 2023-02-16
RU2018107249A (ru) 2019-10-17
JP2018534247A (ja) 2018-11-22
JP2022065075A (ja) 2022-04-26
ES2934714T3 (es) 2023-02-24
AU2016324307A1 (en) 2018-03-22
EP4151228A2 (en) 2023-03-22
CN108135971A (zh) 2018-06-08
AU2016324298B2 (en) 2022-09-01
RU2018107245A3 (pt) 2019-10-18
RU2018107249A3 (pt) 2020-01-10
KR20180052754A (ko) 2018-05-18
US11413334B2 (en) 2022-08-16
JP2018527378A (ja) 2018-09-20
MX2022006525A (es) 2022-07-11
WO2017049242A2 (en) 2017-03-23
HK1256628A1 (zh) 2019-09-27
RU2724545C2 (ru) 2020-06-23
CA2998507A1 (en) 2017-03-23
RU2728682C2 (ru) 2020-07-31
MX2018003100A (es) 2019-04-15
JP7029805B2 (ja) 2022-03-04
AU2016324298A1 (en) 2018-03-22
EP4115897A1 (en) 2023-01-11
IL258122A (en) 2018-05-31
AU2022252850A1 (en) 2022-11-17

Similar Documents

Publication Publication Date Title
BR112018005316A2 (pt) ?uso de lisina para restabelecer/aumentar a atividade antibacteriana na presença de surfactante pulmonar de antibióticos inibidos desse modo?
DOP2018000182A (es) Benzamidas sustituidas con 1,3–tiazol–2–ilo
BR112018013157A2 (pt) composição inoculante aquosa, material de propagação de planta revestido, kit, planta, parte de planta, produto processado, cultura, e, método.
BR112018004620A2 (pt) moduladores da expressão de kras
BR112017009623A2 (pt) composição de limpeza
BR112015024674A2 (pt) método para aumentar a capacidade de sobrevivência de um ou mais microrganismos benéficos e para revestir uma semente, e, composição
BR112017004889A2 (pt) uso antibacteriano de salicilanilidas halogenadas
BR112015032341A2 (pt) conservação de composições para cuidados pessoais
BR112018016729A2 (pt) novo composto de tiofeno substituído nas posições 2,3,5, utilizado como inibidor de proteína quinase
BR112019001980A2 (pt) inibidor de ido1 e método de preparação e aplicação do mesmo
BR112017011422A2 (pt) compostos de ácido isoazol hidro¬xâmico como inibidores de lpxc
BR112016006048A8 (pt) composições antimicrobianas
WO2015168635A3 (en) Compositions and methods for modulating complement factor b expression
AU2017317563A8 (en) Detergent compositions comprising xanthan lyase variants I
BR112014000542A2 (pt) composições de peroxidase eosinofílica e métodos de uso das mesmas
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
PH12017500615A1 (en) Ophthalmic composition comprising cyclosporine and trehalose
BR112016024096A2 (pt) novo bacteriófago e composição compreendendo o mesmo
BR112018002154A2 (pt) sal de colina e adjuvantes isentos de amônio para condicionamento de água e formulações agrícolas
BR112018001486A2 (pt) ?composição de limpeza em barra, processo para preparar a composição, método para reduzir atividade antimicrobiana em uma superfície e uso da composição?
RS54875B1 (sr) Liofilizovane formulacije fgf-18
BR112018069115A2 (pt) composições, composições de revestimento aquosas e métodos para melhorar a estabilidade de congelamento/descongelamento de composições de revestimento aquosas
BR112015023205A2 (pt) composições e métodos para formulações de alfavírus vivo atenuado
BR112015012158A2 (pt) método para tratar um material de tabaco, material de tabaco, artigo para fumar, uso de água subcrítica
AR109407A1 (es) Compuesto de 1-acetil-3-fenilurea y su uso

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]